The phase diagram has a closed-loop binodal (as in associative phase diagrams) with two critical points. One critical point is in common with the strong driving force cases, that is, the system loses ...

June 13, 2025 By Shane O’Brien The city’s Department of Housing Preservation and Development (HPD) has released a Request for Proposal (RFP) to develop Parcel E at Hunters Point South on the Long ...

Construction has officially topped out on the second phase of The Peninsula, a five-building, 100% affordable housing development rising in Hunts Point on the former site of the Spofford Juvenile ...

Over 400 patients enrolled in Phase 3 trials for DURAVYU to treat wet AMD, with data expected in mid-2026. Quiver AI Summary EyePoint Pharmaceuticals announced the successful enrollment and ...

The Phase 3 pivotal programs are evaluating re-dosing of DURAVYU with the goal of providing the retina community valuable insight into sustained ‘real-world’ usage of DURAVYU.

CenterPoint Energy announced it has completed the installation of 400 miles of underground power lines as part of Phase Two of the Greater Houston Resiliency Initiative (GHRI). The infrastructure work ...

Immunic’s lead oral small molecule has failed to hit the primary endpoint of a phase 2 trial in patients with progressive multiple sclerosis (PMS), but the New York biotech is pointing to other ...

III Points is returning to Miami, Florida, this October with another excitingly diverse array of performers. The “phase one” lineup for the music festival includes hardcore (Turnstile), rap ...

Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small, single arm study of patients with brain cancer. The phase 2 Ipax-Linz trial enrolled eight ...

Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive grade 1 or grade 2 GEP-NETs.

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.

The SC formulation of isatuximab showed noninferiority to the IV version in the phase 3 IRAKLIA study for multiple myeloma. The study used an on-body delivery system, enhancing patient convenience ...